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Abstract
The ketoglutarate dehydrogenase complex (KGDHC) consists of three different subunits encoded by OGDH (or OGDHL), 
DLST, and DLD, combined in different stoichiometries. DLD subunit is shared between KGDHC and pyruvate dehydroge-
nase complex, branched-chain alpha-keto acid dehydrogenase complex, and the glycine cleavage system. Despite KGDHC’s 
implication in neurodegenerative diseases, cell-specific localization of its subunits in the adult human brain has never been 
investigated. Here, we show that immunoreactivity of all known isoforms of OGDHL, OGDH, and DLST was detected 
exclusively in neurons of surgical human cortical tissue samples identified by their morphology and visualized by double 
labeling with fluorescent Nissl, while being absent from glia expressing GFAP, Aldhl1, myelin basic protein, Olig2, or IBA1. 
In contrast, DLD immunoreactivity was evident in both neurons and glia. Specificity of anti-KGDHC subunits antisera 
was verified by a decrease in staining of siRNA-treated human cancer cell lines directed against the respective coding gene 
products; furthermore, immunoreactivity of KGDHC subunits in human fibroblasts co-localized > 99% with mitotracker 
orange, while western blotting of 63 post-mortem brain samples and purified recombinant proteins afforded further assur-
ance regarding antisera monospecificity. KGDHC subunit immunoreactivity correlated with data from the Human Protein 
Atlas as well as RNA-Seq data from the Allen Brain Atlas corresponding to genes coding for KGDHC components. Protein 
lysine succinylation, however, was immunohistochemically evident in all cortical cells; this was unexpected, because this 
posttranslational modification requires succinyl-CoA, the product of KGDHC. In view of the fact that glia of the human brain 
cortex lack succinate-CoA ligase, an enzyme producing succinyl-CoA when operating in reverse, protein lysine succinyla-
tion in these cells must exclusively rely on propionate and/or ketone body metabolism or some other yet to be discovered 
pathway encompassing succinyl-CoA.
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Introduction
Ketoglutarate dehydrogenase complex (KGDHC) is a 
multi-subunit enzyme residing in the mitochondrial matrix 
(Maas and Bisswanger 1990). It catalyzes the irreversible 
decarboxylation of α-ketoglutarate (αKg) to succinyl-CoA 
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while reducing  NAD+ to NADH. The complex participates 
in the citric acid cycle exhibiting a high flux-control coef-
ficient in the generation of reducing equivalents (Cooney 
et al. 1981; Sheu and Blass 1999), also contributing to the 
maintenance of the mitochondrial redox state (Gibson et al. 
2000). KGDHC’s influence in the cycle is so significant; 
its activity dictates the directionality of all three of its seg-
ments (Chinopoulos 2013). KGDHC is further involved 
in transaminations and glutamate metabolism (Cooper 
2012), while its product, succinyl-CoA, can be shuttled 
towards heme synthesis (Atamna et  al. 2001; Atamna 
and Frey 2004; Burch et al. 2018), and/or mitochondrial 
substrate-level phosphorylation (mSLP). mSLP is almost 
exclusively attributed to succinyl-CoA ligase (SUCL), the 
enzyme following KGDHC in the citric acid cycle, catalyz-
ing the reversible conversion of succinyl-CoA and ADP 
(or GDP) to CoASH, succinate, and ATP (or GTP) (John-
son et al. 1998). Unimpaired KGDHC activity is critical 
for sustaining mSLP (Kiss et al. 2013). Regulation of the 
complex and its overall impact on energy metabolism has 
been extensively reviewed elsewhere (Gibson et al. 2010; 
Starkov 2013).
More recently, the group of Gibson discovered that 
KGDHC serves as a trans-succinylase, adding succinyl 
moieties to lysines of proteins in an αKg-dependent manner 
(Gibson et al. 2015). Lysine succinylation is a widespread 
posttranslational modification occurring on thousands of 
lysines residing in hundreds of proteins distributed in the 
cytosol, nucleus, and mitochondria (Zhang et  al. 2011; 
Weinert et al. 2013).
Mindful of KGDHC’s involvement in a multitude of bio-
chemical processes, it is not surprising that its deficiency 
leads to pathology, particularly in the brain: indeed, a decline 
in KGDHC activity is associated with Alzheimer’s disease 
(Gibson et al. 1988, 1998, 2000, 2013; Butterworth and Bes-
nard 1990; Mastrogiacoma et al. 1996; Terwel et al. 1998; 
Bubber et al. 2005), Parkinson’s disease (Gibson et al. 2003), 
Huntington’s chorea (Naseri et al. 2015), Wernicke–Korsa-
koff syndrome (Butterworth et al. 1993), and progressive 
supranuclear palsy (Albers et al. 2000; Park et al. 2001). A 
reduction of KGDHC activity is not generally paralleled by 
all other enzymes of the citric acid cycle (Bubber et al. 2005; 
Gibson et al. 2010; Bubber et al. 2011). The reason for this 
selective vulnerability is incompletely understood, but it is 
Table 1  Antibodies used for 
detecting all known human 
KGDHC subunit isoforms
Subunit Isoform Antibody used
OGDHL Q9ULD0-1 Atlas Antibodies, Cat# HPA052497, RRID:AB_2681853
Q9ULD0-2 Proteintech Group, Cat# 17110-1-AP, RRID:AB_2156767
Q9ULD0-3 Proteintech Group, Cat# 17110-1-AP, RRID:AB_2156767
OGDH Q02218-1 Proteintech Group, Cat# 15212-1-AP, RRID:AB_2156759
Q02218-2 Proteintech Group, Cat# 15212-1-AP, RRID:AB_2156759
Q02218-3 Atlas Antibodies, Cat# HPA020347, RRID:AB_1854773
DLST P36957-1 Cell Signaling Technology, Cat# 11954, RRID:AB_2732907
P36957-2 Cell Signaling Technology, Cat# 11954, RRID:AB_2732907
DLD P09622-1 Abcam, Cat# ab133551, RRID:AB_2732908
P09622-2 Abcam, Cat# ab133551, RRID:AB_2732908
P09622-3 Abcam, Cat# ab133551, RRID:AB_2732908
Table 2  Antibodies directed 
against other targets used in this 
study
Target Antibody used
GFAP Santa Cruz Biotech, Cat# sc-33673, RRID:AB_627673
Aldhl1 Abcam, Cat# ab177463, RRID: AB_2811300
Myelin basic protein Abcam, Cat# ab24567, RRID:AB_448144
Olig2 Abcam, Cat# ab109186, RRID: AB_10861310
IBA1 Abcam, Cat# ab107159, RRID:AB_10972670
Succinyl-lysine NovoPro, Cat# 106768, RRID:AB_2732922
VDAC1 Abcam, Cat# ab154856, RRID:AB_2687466
SUCLG1 Abcam, Cat# ab97867, RRID:AB_10678848
SUCLG2 Atlas Antibodies, Cat# HPA046705, RRID:AB_2679762
SUCLA2 Proteintech Group, Cat# 12627-1-AP, RRID:AB_2271200
β-actin Abcam, Cat# ab6276, RRID:AB_2223210
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Fig. 1  The demonstration of 
mitochondrial localization of 
OGDHL, OGDH, DLST, and 
DLD in human fibroblasts using 
the antibodies indicated on the 
left. OGDHL (a, b), OGDH 
(c, d), DLST (e), and DLD (f) 
immunolabeling (labelling by 
Alexa 647) in human fibroblasts 
in relation to mitotracker orange 
(MTO). Scale bars = 30 µm for 
a and c, and 50 µm for b, d–f 
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Fig. 2  The demonstration of 
mitochondrial localization of 
OGDHL, OGDH, DLST, and 
DLD in HeLa cells using the 
antibodies indicated on the left. 
OGDHL (a, b), OGDH (c, d), 
DLST (e), and DLD (f) immu-
nolabeling (labelling by Alexa 
647) in HeLa cells in relation 
to mitotracker orange (MTO). 
Scale bars = 30 µm for a and 
15 µm for b–f 
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likely to be at least partially due to the ability of KGDHC 
of both producing and affected by reactive oxygen species 
(Tretter and Adam-Vizi 2004; Starkov et al. 2004), reviewed 
in (Starkov 2013).
The molecular mechanism(s) linking KGDHC to neu-
rodegeneration are largely unknown; it has been proposed 
that a decrease in complex activity diminishes glucose 
uptake and/or metabolism in the brain—a hallmark of 
Alzheimer’s disease—initiating a sequence of events cul-
minating in neurodegeneration (Chen and Zhong 2013; 
Sang et al. 2018). Laboratory mice modeling neurodegen-
erative diseases cross-bread with those exhibiting KGDHC 
subunit-specific genetic modifications yielded considerable 
insight regarding pathophysiology (Dumont et al. 2009), 
but stopped short in offering a breakthrough regarding 
therapy or even prevention strategy in humans. In most 
neurodegenerative disorders, specific regions of the brain 
are involved, and thus, lack of knowledge on KGDHC 
expression and activity in a cell-specific manner may well 
underlie the lack of progress regarding identifying suitable 
therapeutic targets.
Here, we investigated the cell-specific expression of 
KGDHC subunit components in human cortices obtained 
from surgeries. KGDHC-specific components were detected 
in neurons but not glia. However, protein lysine succinyla-
tion was pancellularly evident. The latter finding was unex-
pected, because succinylation requires succinyl-CoA, the 
product of KGDHC, while glia cannot obtain it from suc-
cinate-CoA ligase as they also lack this enzyme (Dobolyi 
et al. 2015a; b).
Fig. 3  Effect of siRNA (a) vs scramble RNA (b) directed against 
OGDHL isoforms 2 and 3 on OGDHL immunostaining in HeLa 
cells in relation to mitotracker orange (MTO). A reduced intensity 
of OGDHL immunolabeling is visible following siRNA treatment as 
compared to scramble RNA treatment, while siRNA has no effect on 
the labeling with MTO. Scale bars = 50 µm




Human brain samples were collected in accordance to 
the Ethical Rules for Using Human Tissues for Medi-
cal Research in Hungary (HM 34/1999) and the Code of 
Ethics of the World Medical Association (Declaration of 
Helsinki). Ethical permission for obtaining surgical brain 
material for the specific project has been obtained from the 
Medical Research Council of Hungary (No: 35302-5/2017/
EKU), and is valid until June 30th, 2020. Post-mortem tis-
sue samples were taken during brain autopsy in the frame-
work of the Human Brain Tissue Bank (HBTB), Budapest, 
Hungary. HBTB has been authorized by the Committee 
of Science and Research Ethic of the Ministry of Health 
of Hungary (No. 6008/8/2002/ETT) and the Semmelweis 
University Regional Committee of Science and Research 
Ethic (No. 32/1992/TUKEB). For autopsy, brains were 
removed from the skull with a post-mortem delay of 
2–6 h. Prior written informed consent was obtained from 
the patients or from the next of kin for autopsies which 
included the request to conduct neurochemical analyses. 
The protocols including analyses of tissue samples were 
approved by institutional ethics committee of the Semmel-
weis University. The surgical patients (all males) under-
went the removal of brain tumors; samples were obtained 
from normal brain cortical tissue removed during clearing 
the path for accessing the area of the tumor. All patients 
survived the surgery. The subjects whose brains were used 
Fig. 4  Effect of siRNA (a) vs scramble RNA (b) directed against 
OGDHL isoforms 2 and 3 on OGDHL immunostaining in COS-7 
cells in relation to mitotracker orange (MTO). A reduced intensity 
of OGDHL immunolabeling is visible following siRNA treatment as 
compared to scramble RNA treatment, while siRNA has no effect on 
the labeling with MTO. Scale bars = 50 µm
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in the autopsy study died without any known neurological 
or affective disorder. The medical history of the subjects 
was obtained from medical or hospital records, interviews 
with family members and relatives, as well as from patho-
logical and neuropathological reports. All personal identi-
fiers had been removed and samples were coded before the 
analyses of tissue. Surgical samples underwent immedi-
ate fixation (immersed in ice-cold 4% paraformaldehyde 
in 0.1 M phosphate-buffered saline within a few seconds 
after their excision from the brain) for immunolabeling 
used in histochemical techniques. For western blotting, 
autopsy samples from 63 different brain regions of 11 sub-
jects (7 females and 4 males) were obtained by microdis-
section. Individual brain nuclei were microdissected from 
post-mortem brains (that have been rapidly frozen on dry 
ice and stored at − 80 °C) using the micropunch technique 
(Palkovits 1973). Briefly, brains were cut as 1.0–1.5 mm-
thick coronal sections, and individual brain regions and 
nuclei were removed by special punch needles with an 
inside diameter of 1.0–3.5 mm, using either a head mag-
nifier or a stereomicroscope. The microdissected samples 
were collected in Eppendorf tubes and stored at − 80 °C 
until further use. The temperature of brain sections and 
the microdissected samples was kept under 0 °C during 
the whole procedure.
Cell cultures
Fibroblast cultures from skin biopsies were prepared. Cells 
were grown on poly-l-ornithine coated 25 mm round glass 
coverslips for 5–7  days, at a density of approximately 
8 × 105 cells/coverslip in RPMI1640 medium (GIBCO, Life 
Fig. 5  Effect of siRNA (a) vs scramble RNA (b) directed against 
OGDH isoforms 1 and 2 on OGDH immunostaining in HeLa cells in 
relation to mitotracker orange (MTO). A reduced intensity of OGDH 
immunolabeling is visible following siRNA treatment as compared to 
scramble RNA treatment, while siRNA has no effect on the labeling 
with MTO. Scale bars = 50 µm
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technologies, Carlsbad, CA, USA) supplemented with 10% 
fetal bovine serum and 2 mM glutamine and kept at 37 °C in 
5%  CO2. The medium was also supplemented with penicil-
lin, streptomycin, and amphotericin (item A5955, Sigma-
Aldrich St. Louis, MO, USA). HeLa cells were grown on 
poly-l-ornithine coated 25 mm round glass coverslips for 
1–2 days, at a density of approximately 5 × 105 cells/cover-
slip in DMEM (GIBCO) plus glutamine plus 10% fetal calf 
serum and 1% streptomycin-penicillin.
Tissue collection for immunolabeling
For immunocytochemistry, brains were cut into 5–10 mm-
thick coronal slices and immersion-fixed in 4% paraform-
aldehyde in 0.1 M phosphate-buffered saline (PBS) for 
3–5 days. Subsequently, the blocks were transferred to PBS 
containing 0.1% sodium azide for 2 days to remove excess 
paraformaldehyde. Then, the blocks were placed in PBS 
containing 20% sucrose for 2 days for cryoprotection, after 
which the blocks were frozen and cut into 50 μm-thick serial 
coronal sections on a sliding microtome. Sections were col-
lected in PBS containing 0.1% sodium azide and stored at 
4 °C until further processing.
DAB immunolabeling of brain sections
Every fifth free-floating brain section of human temporal 
and frontal cortical blocks was immunostained for KGDHC 
subunits. First, the sections were rinsed in PBS containing 
0.3% Triton X-100 and 1% bovine serum albumin (BSA) for 
1 h to improve antibody penetration and reduce nonspecific 
labeling, respectively. Subsequently, the antibodies were 
Fig. 6  Effect of siRNA (a) vs scramble RNA (b) directed against 
OGDH isoform 3 on OGDH immunostaining in HeLa cells in rela-
tion to mitotracker orange (MTO). A reduced intensity of OGDH 
immunolabeling is visible following siRNA treatment as compared to 
scramble RNA treatment, while siRNA has no effect on the labeling 
with MTO. Scale bars = 50 µm
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applied for 48 h at room temperature, followed by incubation 
of the sections in biotinylated anti-rabbit secondary antibody 
(1:1,000 dilution; Vector Laboratories, Burlingame, CA) and 
then in avidin–biotin–peroxidase complex (1:500; Vector 
Laboratories) for 2 h. Subsequently, the labeling was visu-
alized by incubation in 0.02% 3,3-diaminobenzidine (DAB; 
Sigma), 0.08% nickel (II) sulfate, and 0.001% hydrogen per-
oxide in PBS, pH = 7.4 for 5 min. Sections were mounted, 
dehydrated, and coverslipped with Cytoseal 60 (Stephens 
Scientific, Riverdale, NJ, USA).
Double labeling of in brains sections
KGDHC subunits were immunolabeled using fluorescein 
isothiocyanate (FITC)-tyramide amplification immunohis-
tochemistry, which was followed by labeling neurons and 
glial cells in a subsequent step. FITC-tyramide amplifica-
tion immunolabeling of KGDHC subunits was performed 
as the single labeling except that visualization in the last 
step was done using fluorescein isothiocyanate (FITC)-
tyramide (1:8,000) and  H2O2 in 100 mM Trizma buffer 
(pH 8.0 adjusted with HCl) applied for 6 min, instead of 
DAB. Subsequently, sections were placed in mouse anti-
glial fibrillary acidic protein (GFAP), a marker of astrocytes 
(1:300, Santa Cruz Biotechnology, Delaware, CA, USA; 
see Table 2), rabbit anti-aldehyde dehydrogenase 1 family 
member L1 (Aldhl1), a marker of astrocytes (1:50, Abcam, 
Cambridge, UK; see Table 2), rabbit anti-oligodendrocyte 
transcription factor 2 (Olig2), a marker of oligodendrocytes 
(1:50, Abcam, Cambridge, UK; see Table 2), mouse anti-
myelin basic protein (MBP), a marker of oligodendrocytes 
(1:300, Abcam, Cambridge, UK; see Table  2), or goat 
Fig. 7  Effect of siRNA (a) vs scramble RNA (b) directed against 
DLST isoforms 1 and 2 on DLST immunostaining in HeLa cells in 
relation to mitotracker orange (MTO). A reduced intensity of DLST 
immunolabeling is visible following siRNA treatment as compared to 
scramble RNA treatment, while siRNA has no effect on the labeling 
with MTO. Scale bars = 50 µm
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anti-ionized calcium-binding adaptor molecule 1 (Iba1), a 
marker of microglial cells (1:1000, Abcam, Cambridge, UK; 
see Table 2) for 48 h at room temperature. The sections were 
then incubated in Alexa 594 donkey anti-mouse (or rabbit, 
or goat, respectively) secondary antibody (1:500, Molecular 
Probes, Eugene, OR) for 2 h and washed. For the double 
labeling with Nissl staining, the sections were incubated in 
‘Neurotrace’ red fluorescent Nissl stain (Molecular Probes) 
diluted to 1:30 for 2 h, and washed in PBS overnight. Finally, 
all sections with fluorescent labels were mounted on posi-
tively charged slides (Superfrost Plus, Fisher Scientific, 
Pittsburgh, PA) and coverslipped in antifade medium (Pro-
long Antifade Kit, Molecular Probes).
Immunocytochemistry of cell cultures
Fibroblasts or HeLa (CLS Cat# 300194/p772_HeLa, 
RRID:CVCL_0030) or COS-7 (CLS Cat# 605470/p532_
COS-7, RRID:CVCL_0224) cell cultures were first treated 
with 1 μM Mitotracker Orange (MTO) for 5 min in their 
culture media, at 37 °C in 5%  CO2. Subsequent immuno-
cytochemistry of the cultures was performed by fixing the 
cells with 4% paraformaldehyde in PBS for 20 min, fol-
lowed by permeabilization by 0.1% TX-100 (in PBS) for 
10 min and several washing steps in between with PBS at 
room temperature. Cultures were treated with 10% donkey 
serum overnight at 4 °C followed by bathing in 1% donkey 
serum and a primary antibody as indicated in Tables 1 
and 2 for 12  h at room temperature. Titers are indi-
cated in the respective legends. Cells were subsequently 
Fig. 8  Effect of siRNA (a) vs scramble RNA (b) directed against 
DLD isoforms 1, 2 and 3 on DLD immunostaining in HeLa cells in 
relation to mitotracker orange (MTO). A reduced intensity of DLD 
immunolabeling is visible following siRNA treatment as compared to 
scramble RNA treatment, while siRNA has no effect on the labeling 
with MTO. Scale bars = 50 µm
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decorated using the appropriate Alexa 488-linked or Alexa 
647-linked secondary antibody (1:4,000, donkey anti-rab-
bit, Jackson Immunochemicals Europe Ltd, Cambridgesh-
ire, UK) in the presence of 1% donkey serum.
Western blotting
Frozen brain samples were thawn on ice in the presence 
of radioimmunoprecipitation assay buffer and a protease 
cocktail inhibitor containing: 0.5 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride, 150 nM Apro-
tinin, 1 μM E-64, 0.5 mM EDTA disodium, and 1 μM Leu-
peptin, and homogenized with a Teflon pestle. The suspen-
sions were centrifuged once at 10,000g for 10 min, and 
the proteins present in the supernatants were separated by 
sodium dodecyl sulfate—polyacrylamide gel electropho-
resis (SDS-PAGE). Separated proteins were transferred 
to a methanol-activated polyvinylidene difluoride mem-
brane. Immunoblotting was performed as recommended 
by the manufacturers of the antibodies, see Tables 1 and 2. 
Immunoreactivity was detected using the appropriate per-
oxidase-linked secondary antibody (1:4,000, donkey anti-
mouse or anti-rabbit, Jackson Immunochemicals Europe 
Ltd, Cambridgeshire, UK) and enhanced chemilumines-
cence detection reagent (ECL system; Amersham Bio-
sciences GE Healthcare Europe GmbH, Vienna, Austria).
Image processing
The sections were examined using an Olympus BX60 
light microscope equipped with bright-field, dark-field and 
fluorescence. Images were captured at 2048 × 2048 pixel 
resolution with an SPOT Xplorer digital CCD camera 
(Diagnostic Instruments, Sterling Heights, MI, USA) using 
a 4 × objective for dark-field images, and 4–40 × objectives 
for bright-field and fluorescent images. Fluorescent sections 
were also evaluated using a Bio-Rad 2100 Rainbow Confo-
cal System (Bio-Rad Laboratories, Inc, CA, USA). The con-
trast and sharpness of the images were adjusted using the 
“levels” and “sharpness” commands in Adobe Photoshop 
CS 8.0. Full resolution was maintained until the photomi-
crographs were finally cropped at which point the images 
were adjusted to a resolution of 300 dpi.
siRNA and cell transfections
The ON-TARGETplus SMARTpool containing four differ-
ent siRNA sequences, all specific to human KGDHC-specific 
components (see under “Results”) and the corresponding non-
targeting control (scrambled RNA), were designed by Thermo 
Scientific Dharmacon and synthesized by Sigma-Aldrich. 
HeLa cells were transfected with 100 nM of either siRNA or 
scrambled siRNA using Lipofectamine 2000 according to the 
manufacturer’s instructions, 48 h before immunocytochemistry.
Fig. 9  Immunoreactivities of the proteins indicated on the left in 
brain tissue homogenates (indicated on the top; individual samples 
coded by a three-digit number obtained from brain regions as detailed 
in Table  3). The most-left lane includes purified, recombinant pro-
teins (Prot.) for SUCLG1, SUCLG2, OGDH, DLST, and DLD
650 Brain Structure and Function (2020) 225:639–667
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Results
Antibody selection for detecting all known KGDHC 
subunit human isoforms
KGDHC consists of multiple copies of three subunits: 
oxoglutarate dehydrogenase (OGDH) or oxoglutarate 
dehydrogenase-like protein (OGDHL), dihydrolipoyl suc-
cinyltransferase (DLST), and dihydrolipoyl dehydrogenase 
(DLD). OGDHL exhibits three isoforms Q9ULD0-1, 
Table 3  Brain regions of origin of samples







169 Cerebral white matter
148 Insular cortex
139 Cerebral white matter
502 Temporal cortex
963 Insular cortex




881 Cerebral white matter
889 Somatomotor cortex
725 Insular cortex
877 Dorsomedial prefrontal cortex
895 Temporal cortex
494 Anterior cingulate cortex
879 Frontopolar cortex
971 Frontal cortex




458 Cerebral white matter (frontal)
717 Cerebral white matter (frontal)
724 Temporal cortex
129 Somatomotor cortex
592 Cerebral white matter (frontal)
459 Frontal cortex
715 Frontal cortex
878 Ventrolateral prefrontal cortex
781 Posterior cingulate cortex
127 Somatosensory cortex
973 Temporal cortex
734 Posterior cingulate cortex
508 Posterior cingulate cortex
141 Cerebral white matter (frontal)
862 Posterior cingulate cortex
854 Entorhinal cortex
199 Anterior cingulate cortex
744 Cerebral white matter (frontal)
210 Temporal cortex
130 Temporal cortex
913 medial geniculate body
193 Frontal cortex
847 Anterior cingulate cortex
Table 3  (continued)
Sample identifier Brain region
716 Anterior cingulate cortex
908 Frontal cortex
841 Insular cortex
513 Posterior cingulate cortex








600 Cerebral white matter (frontal)
Fig. 10  OGDHL immunolabeling in the human cerebral cortex in 
relation to neuronal and glial markers. a OGDHL isoform 1-immu-
noreactive cells are present the cerebral cortex, with higher density 
in the deep layers. b OGDHL isoform 1 (green) and fluorescent Nissl 
staining (red) show many double-labeled yellow cells in the cerebral 
cortex. c A higher magnification confocal image of a cerebral corti-
cal section double stained with OGDHL isoform 1 (green) and fluo-
rescent Nissl staining (red) demonstrates that larger, neuronal cells 
(some of them indicated with white arrow) are double labeled. Sev-
eral small cells are also present, which are not labeled with OGDHL 
isoform 1. Please observe the dot-like intracellular labeling pattern of 
OGDHL subunit 1 immunoreactivity. d A cerebral cortical section 
double labeled with OGDHL isoform 1 (green) and the established 
astrocyte marker glial fibrillary acidic protein (GFAP; red) shows 
only single-labeled cells positive for OGDHL isoform 1 or for GFAP, 
demonstrating that astrocytes are not labeled with OGDHL isoform 
1. Some of the single-labeled astrocytes are pointed to by white 
arrowheads. e A confocal image of a cerebral cortical section dou-
ble stained with OGDHL isoform 2/3 (green) and fluorescent Nissl 
staining (red) demonstrates that larger, neuronal cells (some of them 
indicated with white arrow) are double labeled. Several small cells 
not labeled with OGDHL isoform 2/3 are also present. Note the dot-
like intracellular labeling pattern of OGDHL subunit 2/3 immuno-
reactivity. f A cerebral cortical section double labeled with OGDHL 
isoform 2/3 (green) and GFAP (red) shows cells labeled either with 
OGDHL or with GFAP, demonstrating that astrocytes are not labeled 
with OGDHL isoform 2/3. Some of the single-labeled astrocytes are 
pointed to by white arrowheads. Scale bars = 200 µm for a, 300 µm 
for b, 100 µm for c–f 
◂
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Q9ULD0-2 and Q9ULD0-3; OGDH 3 isoforms: Q02218-
1, Q02218-2 and Q02218-3; DLST 2 isoforms: P36957-1 
and P36957-2; and DLD 3 isoforms: P09622-1, P09622-2 
and P09622-3. By knowing the amino acid sequence of 
each isoform, we could select antibodies raised using 
epitopes recognizing all isoforms, see Table 1. Whenever 
the same antibody is used for more than one isoform, this 
is because the epitope is within a 100% aligning region 
between the isoforms. More antibodies were probed that 
yielded no staining and these were excluded from this 
study.
Antibody validation
Antibodies directed against KGDHC subunit isoforms were 
validated by the following protocols: (1) > 99% co-localiza-
tion with mitotracker orange (a dye that stains exclusively 
mitochondria) in human fibroblasts; (2) decrease in immu-
nocytochemical staining of siRNA—but not scramble RNA-
treated human cell lines silencing genes that code KGDHC 
subunit isoforms and decorated by the same antibodies; 
(3) emergence of only one band at the expected molecular 
weight in Western blots probing purified, recombinant pro-
teins, and human brain homogenate samples.
As shown in Fig.  1, normal human fibroblasts were 
treated with the antibodies indicated on the left and detected 
with secondary antibodies conjugated with Alexa 647 fluo-
rophore (left panels, green); their mitochondrial network 
was selectively stained by loading cells with Mitotracker 
Orange (MTO, 1 μM, middle panels, red) prior to fixation. 
Co-localization of Alexa 647 and MTO staining is shown 
in the panels to the right. From the right-hand panels, it is 
evident that except for antibody HPA052497 directed against 
isoform 1 of OGDHL (Q9ULD0-1), all other antibodies 
yielded > 99% of co-localization with the mitochondrial 
network. Regarding Q9ULD0-1, at this junction, it cannot 
be distinguished if the lack of co-localization of the antibody 
with MTO is due to lack of specificity, or Q9ULD0-1 is not 
sufficiently expressed in human fibroblasts. Nonetheless, the 
robust co-localization of all other antibodies with MTO in 
these confocal images proved that the antigens are located 
within mitochondria.
Next, to investigate if the intramitochondrial decoration 
is due to antigens belonging to the intended proteins against 
which the KGDHC subunit and isoform-specific antibodies 
were raised, cell lines were transfected with either siRNA 
directed against individual subunits belonging to KGDHC 
or scramble RNA, and subsequently co-stained with the 
same antibodies and MTO. For these experiments, cancer 
cell lines (HeLa and COS-7) were used instead of fibro-
blasts, because the former exhibit much higher transfection 
efficiencies than the latter. COS-7 is a cell line originating 
from monkey kidney tissue, but it was probed for OGDHL 
isoforms 2 and 3 which are identical to those expressed in 
humans. Other cell lines tested did not yield a sufficiently 
clear mitochondrial network for co-localization studies 
(not shown). As shown in Fig. 2, HeLa cells were treated 
with the antibodies indicated on the left and decorated with 
secondary antibodies conjugated with Alexa 647 fluoro-
phore (left panels, green); their mitochondrial network 
was selectively stained by loading cells with MTO (1 μM, 
middle panels, red) prior to fixation. Co-localization of 
Alexa 647 and MTO staining is shown in the panels to 
the right. The robust co-localization of all antibodies 
(except HPA052497) with MTO in these confocal images 
proved that the antigens are located within mitochondria 
of HeLa cells as well. As shown in the top rows of Figs. 3, 
4, 5, 6, 7, and 8, cells were treated with siRNA directed 
against the respective protein, and in the bottom rows with 
scramble RNA. Alexa 647 decoration is shown in panels 
to the left, while MTO staining is shown in the panels to 
the right. It is evident that the mitochondrial staining for 
KGDHC subunits shown in siRNA-treated cells (top-left 
images) appears weaker than the scramble RNA-treated 
cells (bottom-left panels); furthermore, in some instances 
(top left panels in Figs. 5, 6, and 8), the mitochondrial net-
work of siRNA-treated cells is more fragmented than those 
treated with the scramble RNA. The decrease in staining 
together with the alterations in mitochondrial network in 
siRNA-treated but not scramble RNA-treated cells strongly 
argues that the antibodies used are specific for the intended 
KGDHC subunit proteins. It must be noted that in some 
panels, immunoreactivity with siRNA may appear similar 
Fig. 11  OGDH immunolabeling in the human cerebral cortex in 
relation to neuronal and glial markers. a OGDH isoform 1/2 (green) 
immunolabeling and fluorescent Nissl staining (red) show many 
double-labeled yellow cells in the cerebral cortex. b A high magni-
fication confocal image of a cerebral cortical section double stained 
with OGDH isoform 1/2 (green) and fluorescent Nissl staining (red) 
demonstrates that larger, neuronal cells indicated with white arrow 
are double labeled. Several small cells are also present, which are 
not labeled with OGDH isoform 1/2. Note the dot-like intracellular 
labeling pattern of OGDH subunit 1/2 immunoreactivity. c A cere-
bral cortical section double labeled with OGDH isoform 1/2 (green) 
and the established astrocyte marker glial fibrillary acidic protein 
(GFAP; red) shows only single-labeled cells positive for OGDH iso-
form 1/2 or for GFAP, demonstrating that astrocytes are not labeled 
with OGDH isoform 1. d A high magnification confocal image shows 
separate single OGDH isoform 1/2 and GFAP-positive (red, pointed 
to by arrowheads) cells. e A confocal image of a cerebral cortical sec-
tion double stained with OGDH isoform 3 (green) and fluorescent 
Nissl staining (red) demonstrates that larger, neuronal cells (some of 
them indicated with white arrow) are double labeled. Several small 
cells not labeled with OGDH isoform 3 are also present. f A cerebral 
cortical section double labeled with OGDH isoform 3 (green) and 
GFAP (red) shows cells labeled either with OGDH isoform 3 or with 
GFAP, demonstrating that astrocytes are not labeled with OGDH iso-
form 3. Some of the single-labeled astrocytes are pointed to by white 
arrowheads. Scale bars = 200  µm for a, 30  µm for b, 100  µm for c, 
25 µm for d, and 50 µm for e and f 
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to immunoreactivity without any intervention; however, 
by semi-quantitating emitted light intensity of the signal 
minus the background, immunoreactivity presented for si 
RNA is consistently lower than that for scramble RNA (not 
shown).
Subsequently, to afford further assurance that the anti-
bodies used exhibit monospecificity for the intended pro-
teins -which cannot be addressed by immunocytochemis-
try—and they yield reproducible results from a sufficiently 
high number of tissues, we performed western blotting 
analysis on purified, recombinant proteins (Nemeria et al. 
2014; Ambrus et al. 2016) and 63 human brain homogen-
ates obtained from 11 cadaveric brain donors. All anti-
bodies are directed against short stretches of amino acid 
sequences (which was important for selecting isoform-spe-
cific antibodies), and thus, they were expected to perform 
equally well in western blotting protocols where protein 
folding is lost due to the presence of strong detergents. 
Antibody-selling company policies prohibit the publication 
of the epitopes (to which the authors disagree). As shown 
Fig. 12  OGDHL and OGDH immunolabeling in the human cer-
ebral cortex in relation to glial markers. a OGDHL-immunoreactive 
(green) cells as well as ALDHL1-positive (red) astrocytes are both 
present in the cerebral cortex without any visible co-localization. b 
A high magnification confocal image of the area pointed to by the 
white arrow in a demonstrates that OGDHL-ir cells are not labeled 
with Aldhl1 and in turn, Aldhl1-ir astrocytes do not contain OGDHL 
immunoreactivity. c Aldhl1 (red) is also absent in OGDH-ir cells and 
their processes (green). d The image demonstrates the lack of co-
localization between OGDHL immunoreactivity (green) and the oli-
godendrocyte marker Olig2 (red). Scale bars = 50 μm for a, c, and d, 
and 10 μm for b 
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in Fig. 9, recombinant proteins (shown on the left-most 
lane) and the brain homogenates were probed for SUCLG1, 
SUCLG2, SUCLA2, OGDH, DLST, DLD, β-actin, and 
VDAC1. Antibodies directed against OGDHL isoforms 
were not suitable for western blotting. Since the number 
of the homogenates used was higher than the number of 
lanes per gel that could be loaded, samples loaded in the 
last four lanes of each gel was also loaded in the first four 
lanes of the next gel. β-actin and VDAC1 served as loading 
markers for total tissue homogenate and mitochondrial con-
tent, respectively. SUCLG1, SUCLG2, and SUCLA2 cor-
respond to subunits of succinate-CoA ligase, the enzyme 
following KGDHC in the citric acid cycle. On the top lane, 
each three-digit number represents a brain homogenate 
sample from a brain donor. The exact brain location from 
where these homogenates originated is shown in Table 3. 
As shown in the cropped scanned western blots, the anti-
bodies raised against OGDH, DLST, and DLD yielded a 
Fig. 13  OGDH immunolabeling in the human cerebral cortex in rela-
tion to microglia and oligodendrocyte markers. a OGDH isoform 1/2 
(green) and Iba1 (red) immunolabeling suggest a distinct distribu-
tion of OGDH-containing cells and microglia. In low magnification, 
OGDH- and IBA1-co-immunoreactivity may appear, but this notion 
is rejected in high magnification microphotographs. b A high mag-
nification, optically 1 µm-thick confocal image of a cerebral cortical 
section double stained with OGDH isoform 1/2 (green) and Iba1 (red) 
demonstrates that larger, neuronal cells are single labeled for OGDH 
isoform 1/2. Several small cells are IBA1-positive. These cells are not 
labeled with OGDH isoform ½, suggesting that that microglial cells 
are negative for OGDH isoform 1/2. c A cerebral cortical section 
double labeled with OGDH isoform 1/2 (green) and the established 
oligodendrocyte marker myelin basic protein (MBP; red). The lat-
ter shows the typical distribution of myelinated fibers in the cerebral 
cortex. d A high magnification confocal image shows the lack of co-
localization between OGDH isoform 1/2 and MBP-positive structures 
(red). Scale bars = 200 µm for a and c, 25 µm for b, and 50 µm for d 
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band which appeared at the same molecular weight as the 
recombinant protein. Antibodies for SUCLG1, SUCLG2, 
and SUCLA2 have been validated elsewhere (Dobolyi et al. 
2015a; b; Chinopoulos et al. 2018). Scanned images of 
whole blots appear in the supplemental material. In sup-
plemental Fig. 1, it is shown that antibodies yielded—in 
the vast majority of cases—a single band at the expected 
molecular weight; when the blots were “overexposed”, 
several new bands appeared that were much fainter than 
the band corresponding to the intended protein. From the 
results shown in western blots and confocal imaging of 
immunocytochemistry, we concluded that the antibodies 
raised against KGDHC components are specific to the 
intended proteins. However, it must be emphasized that this 
did not apply for those raised against OGDHL isoforms.
KGDHC subunit‑ and isoform‑specific 
immunoreactivity in human brain cortex and cell 
types identification by co‑staining with neuronal 
and/or glial markers
Using the above validated antibodies, we performed 
immunohistochemistry in human cerebral cortical mate-
rial obtained from neurosurgical interventions. Frontal 
and temporal cortical samples did not show any visible 
difference in their labeling pattern for any antibody. The 
distribution of OGDH subunits investigated with anti-
bodies specific to different OGDHL and OGDH isoforms 
was similar (Figs. 10 and 11, respectively). Labeled cells 
were scarce in layer I of the cerebral cortex (Fig. 10a). In 
contrast, a high number of labeled cells were present in 
all other layers of the cerebral cortex (Fig. 10a and 11a). 
The labeling was absent in the nuclei of the cells, while 
it was punctate with occasional filamentous appearance 
in the perikarya. Although in situ mitochondria are fila-
mentous, a largely punctate appearance emerged likely 
because of the multiple amplification steps. Furthermore, 
immunohistochemistry protocols of signal amplifica-
tion almost always lead to diminished spatial resolution. 
Thus, KGDHC staining in the human cerebral cortical tis-
sue did not completely match the filamentous mitochon-
drial network commonly observed in cultured fibroblasts 
Fig. 14  DLST immunolabeling in the human cerebral cortex in rela-
tion to neuronal and glial markers. a DLST-immunoreactive (DLST-
ir) cells are present in the cerebral cortex, with higher density in the 
deep layers. b DLST (green) and fluorescent Nissl staining (red) show 
that many cells are double-labeled in the cerebral cortex. Arrows 
point to double-labeled neurons, while black arrowheads point to 
single-labeled, DLST-immunonegative cells. Please note the dot-like 
distribution of DLST immunolabeling in the double-labeled neurons. 
c A cerebral cortical section double labeled with DLST (green) and 
the established astrocyte marker glial fibrillary acidic protein (GFAP; 
red) to show the lack of double labeling, suggesting that astrocytes 
are devoid of DLST. White arrowheads point to single-labeled 
(DLST-ir) neurons, while black arrowheads point to single-labeled 
(GFAP-ir) astrocytes. Scale bars = 300 µm for a, and 30 µm for b and 
c 
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and cell lines, but its appearance was still indicative of 
mitochondrial localization.
To identify the type of cells labeled with the differ-
ent OGDH subtypes, double labeling was performed. 
A fluorescent Nissl dye allowed the analysis of cellular 
morphology, which suggested the presence of all OGDH 
subtypes in neurons. In addition, a high number of smaller 
cells, also labeled with fluorescent Nissl dye, were also 
present, but did not contain OGDH. Since the smaller 
size and the even distribution of these cells suggested that 
Fig. 15  DLD immunolabeling in the human cerebral cortex in rela-
tion to neuronal and glial markers. a DLD-immunoreactive (DLD-ir) 
cells are present in layer 1 and also in deep layers of the cerebral cor-
tex. The density of labeled cells is particularly high in layer 1 and the 
pyramidal layers. b DLD (green) and fluorescent Nissl staining (red) 
show that most cells are yellow, that is double-labeled in the cerebral 
cortex. c A cerebral cortical section double labeled with DLD (green) 
and the established astrocyte marker glial fibrillary acidic protein 
(GFAP; red) to show that most astrocyte contain DLD. b1–3 A high 
magnification confocal image of the cerebral cortical section double 
labeled with DLD (green) and fluorescent Nissl staining (red) dem-
onstrates double labeling of the cells. The arrows point to some of the 
double-labeled cells. b1 shows the green channel, b2 the red channel, 
and b3 the merged figure. c1–3 A high magnification confocal image 
of the cerebral cortical section double labeled with DLD (green) and 
GFAP (red) demonstrates the presence of DLD in astrocytes (arrows). 
The arrowheads in turn point to neurons, which contain DLD, but do 
not express GFAP. c1 shows the green channel, c2 the red channel, 
and c3 the merged figure. Scale bars = 300 µm for a, 200 µm for b, 
100 µm for c, and 20 µm for b1–3 and c1–3















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































660 Brain Structure and Function (2020) 225:639–667
1 3
they may be glial cells, we performed double labeling 
with antibodies recognizing different OGDH subtypes 
and the astrocyte markers GFAP (Figs. 10 and 11) and 
Aldhl1 (Fig. 12). The results of these doubly labeling stud-
ies indicated the absence of OGDH immunoreactivity in 
astrocytes. Double labelling of OGDH subunits with the 
oligodendrocyte markers Olig2 (Fig. 12) and myelin basic 
protein (Fig. 13), or the microglial marker IBA1 (Fig. 13) 
also precluded localization of this KGDHC-specific subu-
nit in oligodendroglia and microglia cells, respectively.
Other subunits of KGDHC were examined in similar 
manner. DLST exhibited a distribution and localization 
resembling that of OGDH (Fig. 14a). In contrast, DLD was 
abundant in layer I as well as the deep layers of both the 
frontal and temporal cortices (Fig. 15a). Double labeling 
with the fluorescent Nissl dye suggested that all cells con-
tain DLD (Fig. 15b). Indeed, astrocytes labeled with GFAP 
were shown to also localize DLD in them (Fig. 15c).
Comparison of immunohistochemistry results 
obtained in this study from KGDHC subunit staining 
and those published in the Human Protein Atlas
The Tissue Atlas branch of the Human Protein Atlas aims 
to map the distribution of all human proteins in major tis-
sues and organs, including the brain (Uhlen et al. 2015). 
The Tissue Atlas profiles proteins by antibodies in a quali-
tative manner. More specifically, antibodies are labeled 
with 3,3′-diaminobenzidine (DAB) yielding a brown 
discoloration of the labeled cell. Furthermore, the sec-
tion is also counterstained with hematoxylin and cells are 
identified by visualizing their microscopical characteris-
tics. With this approach, the spatial distribution, cell type 
specificity, and approximate relative abundance of proteins 
can be estimated, in the respective tissues. In Tables 4, 
5, 6, 7, and 8, data from the Human Protein Atlas on 
brain tissues are shown when using KGDHC subunit- and 
isoform-specific antibodies. The Atlas categorizes stain-
ing as ‘high’, ‘medium’, or ‘low’, recognizing ‘glial’ and 
‘neuronal’ staining. As shown in Tables 4, 5, 6, 7, and 
8, in the human cortex, OGDH, OGDHL, and DLST are 
mostly expressed in neurons (medium or high staining), 
and they exhibit a low expression in glia. DLD staining is 
medium for both neurons and glia. It must be emphasized 
that visual identification of neurons versus glia by DAB 
followed by hematoxylin counterstain is prone to high 
false-positive and false-negative results. In the present 
work, cells were identified by Nissl, GFAP, IBA1, Olig2, 
Aldhl1, and myelin basic protein, affording a very high 
level of assurance regarding correct cell identification and 
categorization. Nevertheless, there is an obvious agree-
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Protein Atlas, namely that KGDHC-specific subunits are 
expressed in neurons and little (if at all) in cortical glia.    
Correlation of immunohistochemistry results 
obtained in this study from KGDHC subunit staining 
and RNA‑Seq data published in the Allen Brain Atlas
The Allen Brain Atlas is an integrated spatio-temporal portal 
for exploring the central nervous system (Sunkin et al. 2013). 
It entails—among other databases—RNA-Seq data from 
intact nuclei derived from frozen human brain specimens 
obtained from middle temporal gyri. Specifically, 15,928 
nuclei from 8 human tissue donors ranging in age from 
24–66 years were analyzed. As shown in Fig. 16a, RNA-
Seq data for OGDH, OGDHL, DLST, and DLD (indicated 
on the left) are shown as a function of cell subtype (indicated 
in the x-axis). These data are pooled exclusively from the 
exons. It is immediately apparent that, in non-neuronal cells, 
thus including glia- expression of KGDHC components is 
much less than that in glutamatergic + GABA-ergic cells, 
i.e., collectively neuronal cells. For comparisons, RNA-Seq 
data for GFAP and Olig2 (glial markers), SLC17A7 (Sol-
ute Carrier Family 1 (Glutamate Transporter), Member 7; 
it transports L-glutamate; glutamatergic neuron marker), 
GAD1: Glutamate Decarboxylase isoform 1; GABA-ergic 
neuronal marker and SUCLA2 (component of ATP-forming 
succinate-CoA ligase, neuronal marker) are also presented. 
On the other hand, in Fig. 16b, RNA-Seq data from introns 
only are presented, and there, it is apparent that gene ele-
ments coding for KGDHC components are essentially the 
same between neuronal vs non-neuronal cells; this practi-
cally means that in non-neuronal cells (such as glia), genes 
coding for KGDHC components are embedded in intronic 
regions as a result of some genetic regulation.
Fig. 16  RNA-Seq data obtained from the Allen Brain Atlas, looking at the expression of genes indicated in the left, as a function of cell types. a 
Genes found only in exons. b Genes found only in introns. Image credit: Allen Institute. https ://cellt ypes.brain -map.org/rnase q/human 
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Protein lysine succinylation is pancellularly evident 
in the human brain
All cells in the examined cerebral cortices were immune-
positive for protein lysine succinylation (Fig.  17a) as 
demonstrated by the lack of cells singly labelled with the 
fluorescent Nissl dye (Fig. 17b). The localization in astro-
cytes was also confirmed by double labeling with GFAP as 
indeed all GFAP-positive glial cells contained immunola-
beling for protein lysine succinylation, as well (Fig. 17c). 
The specificity of the labeling was confirmed by the absence 
of signal when the antibody was pre-incubated with suc-
cinylated Wheat Germ Agglutinin (WGA, Fig. 18b, d) but 
not WGA without succinylation Fig. 18a, c). Specificity 
of the anti-succinyllysine antibody was further assured by 
an independent methodology, Western blotting (WB) of 
homogenized brains. As shown in Fig. 18e–h, WB for 12 
different brain homogenates was performed. In the same 
gels, wheat germ agglutinin (WGA) and succinylated WGA 
were loaded where indicated. In panel E, blots were probed 
with anti-succinyllysine antibody; the blot shown in panel F 
was treated with anti-succinyllysine antibody plus WGA; the 
blot shown in panel G was treated with anti-succinyllysine 
antibody plus succinylated WGA; and the blot strip shown in 
panel H depicts the result of probing for β -actin, as loading 
control. It is evident that incubation of the anti-succinylly-
sine antibody with succinylated WGA (Fig. 18g) but not 
WGA (Fig. 18f) yields very little staining. WGA contains 
endogenous succinylated sites (Zhang et al. 2017), and thus, 
a band is visible in the respective lane. 
Proposed metabolic differences (pertinent 
to KGDHC) between neurons and glia in the adult 
human cortex
The above results indicate that glia of the human brain 
lack KGDHC. Mindful of the previously published work 
shows that they also lack succinate-CoA ligase (Dobolyi 
et al. 2015a; b), and the segment of the citric acid cycle 
from α-ketoglutarate to succinate could only be connected 
through the GABA shunt, a pathway which is known to 
take place in glia (Minelli et al. 1996; Conti et al. 1998, 
1999). However, succinyl-CoA is still being made since 
protein lysine succinylations were detected in these cells 
as well. Thus, we propose the following metabolism 
Fig. 17  Succinyl-lysine immunolabeling in the human cerebral 
cortex in relation to neuronal and glial markers. a Succinyl-lysine-
immunoreactive (SUCCLYS-ir) cells are present in the cerebral cor-
tex, with higher density in the deep layers. b Succinyl-lysine (green) 
and fluorescent Nissl staining (red) show that essentially all cells are 
double-labeled in the cerebral cortex. Arrows point to some of these 
double-labeled cells. Note the dot-like distribution of succinyl-lysine 
immunolabeling in the double-labeled cells. c A cerebral cortical sec-
tion double labeled with succinyl-lysine (green) and the established 
astrocyte marker glial fibrillary acidic protein (GFAP; red) to show 
the double labeling of astrocytes. White arrowheads point to single-
labeled (SUCCLYS-ir) neurons. Scale bars = 300 µm for a and 30 µm 
for b and c 
▸
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pertinent to KGDHC in neurons versus glia: as shown 
in Fig.  19, neuronal mitochondria (blue box) perform 
the citric acid cycle as described in textbooks. They also 
receive glutamine (Gln) from the extracellular space (EC), 
which originated from glia as part of the so-called “glu-
tamate–glutamine cycle” between neurons and glia (Son-
newald and Schousboe 2016). Some neurons will also 
extrude GABA to the EC, which can be taken up by the 
glia. Glial mitochondria (orange box), on the other hand, 
will also take up glutamate from the EC, which has been 
released by neurons and further process it by transamina-
tion or use it for forming GABA. Succinyl-CoA in glia 
can only be produced from valine, isoleucine, methionine, 
thymine, odd-number chain fatty acids, and, perhaps, pro-
pionate (multiple reactions, omitted for clarity), and from 
the reaction catalyzed by OXCT1, an enzyme participat-
ing in ketone bodies catabolism; relevant to this, ketone 
bodies metabolism is known to occur in human astrocytes 
(Thevenet et al. 2016).
Discussion
The two most important observations of the present work are 
that (1) we detected KGDHC-specific subunits immunore-
activity in neurons but not glia of the human brain, and (2) 
protein lysine succinylations were pancellularly observed, 
thus, in glia, succinyl-CoA is probably a product of an 
enzyme other than KGDHC. Furthermore, to the best of our 
knowledge, our work is the first to demonstrate protein lysine 
succinylation in the adult human cortex. DLD subunit was 
found also in non-neuronal cells, but this is probably due 
to its participation in the pyruvate dehydrogenase complex, 
branched-chain alpha-keto acid dehydrogenase complex, and 
the glycine cleavage system.
Regarding the finding that KGDHC-specific compo-
nents were not observed in cells staining positive with 
Fig. 18  Testing of the specificity of the anti-succinyl-lysine antibody 
by absorption in the human cerebral cortex. a Preincubation of the 
anti-succinyl-lysine antibody with wheat germ agglutinin does not 
prevent immunolabeling. The arrow indicates the area magnified in 
c. b Following preincubation of the anti-succinyl-lysine antibody 
with succinylated wheat germ agglutinin, no labeled cells are present 
suggesting that the preincubation eliminates specific immunolabe-
ling in a section adjacent to the one shown in a. c, d Higher magni-
fication images confirm the effect of preabsorption with succinylated 
wheat germ agglutinin. Note the different types of labelled cells in c 
as arrows point to larger cells, probably neurons while arrowheads 
point to small cells with several processes resembling glial cells. 
Scale bars = 200 μm for a and b, and 50 μm for c and d. e Western 
blot loaded with 12 brain homogenates, WGA-loaded lane and suc-
cinylated WGA, where indicated, treated with anti-succinyllysine. 
f Same as for e, treated with WGA plus anti-succinyllysine. g Same 
as for e but treated with succinylated WGA plus anti-succinyllysine, 
which effectively eliminated the labeling. h β-actin as loading control
▸
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glial markers, it is important to emphasize that our immu-
nohistochemistry protocols included several amplification 
steps. This implies that if KGDHC-specific components 
are expressed in human glia, they are probably at least two 
orders of magnitude less abundant than those expressed 
in neurons, precluding the possibility of an appreciable 
KGDHC activity in the former cell types. The group of John 
P Blass has also published the absence of KGDHC immuno-
reactivity from glia in the adult human brain; however, out of 
perhaps abundance of caution, they reported it as “surpris-
ingly, convincing immunoreactivity was not found in glia” 
(Ko et al. 2001), even though KGDHC immunoreactivity 
was completely absent from all of their microphotographs. 
Here, we investigated glial cells exhibiting GFAP, Aldhl1, 
myelin basic protein, Olig2, and IBA1, identifying astro-
cytes, oligodendrocytes, and microglia. However, the human 
brain harbors hundreds (if not thousands) of cell types and 
subtypes. The Human Brain Project aims to identify and cat-
alogue all these cells (Amunts et al. 2016). Thus, it cannot be 
excluded that some glial subtypes exhibit KGDHC-specific 
components to a detectable level. This is supported by RNA-
Seq data obtained from the Allen Brain Atlas, in which posi-
tive “hits” were scarce but still visible in non-neuronal cells. 
The notion that glia of the adult human brain may not exhibit 
KGDHC (nor succinyl-CoA ligase) activity, thus preclud-
ing operation of the citric acid cycle as we know it calling 
for reconsideration of a textbook definition of a universal 
metabolic pathway should not come as a great surprise: 
mice engineered to lack cytochrome c oxidase in astrocytic 
mitochondria in vivo were fully viable in the absence of any 
signs of glial or neuronal loss even at 1 year of age (Sup-
plie et al. 2017). Notably though, KGDHC (detected immu-
nologically using an antibody generated using the whole 
complex as an epitope) has been reported in astrocytes of 
cerebrum and cerebellum of newborn mice (Waagepetersen 
et al. 2006). Furthermore, in (Calingasan et al. 1994), it was 
shown that in 3-month-old male Fischer 344/Brown Norway 
F1 hybrid rats immunohistochemistry for KGDHC (using 
an anti-rabbit IgG for KGDHC, no further information is 
provided), KGDHC stained neurons much more intensely 
than glia in several brain areas. Perhaps, KGDHC is absent 
(or at least present at an extremely small level) in human 
glia so as to assist the glutamate-glutamine cycle by pre-
venting glutamate catabolism through the citric acid cycle 
(which necessitates KGDHC activity), instead being shuttled 
towards glutamine formation. By the same token, glutamate 
taken up from the EC would be shuttled towards GABA 
metabolism, also known to operate in glia cells. Relevant 
to this, in a human embryonic kidney cell line, even a mild 
reduction (~ 30%) in KGDHC activity elevated the GABA 
shunt (Shi et al. 2009).
Regarding the observation of pancellular lysine suc-
cinylation in the adult human cortex in view of the fact 
that glia may not exhibit KGDHC nor succinyl-CoA ligase 
Fig. 19  Metabolic considerations of a neuronal mitochondrion (blue 
box) and a glial mitochondrion (orange box) pertinent to KGDHC. 
AC aconitase, BDH β-hydroxybutyrate dehydrogenase, CS citrate syn-
thase, FH fumarase, GAD glutamate decarboxylase, GABA-T GABA 
aminotransferase, GDH glutamate dehydrogenase, GLSc glutaminase 
(cytosolic), GLSm glutaminase (mitochondrial), GOT2 aspartate ami-
notransferase, IDH isocitrate dehydrogenase, KGDHC ketoglutarate 
dehydrogenase complex, MDH malate dehydrogenase (mitochon-
drial), OXCT1 succinyl-CoA:3-oxoacid CoA-transferase, PC pyruvate 
carboxylase, PDHC pyruvate dehydrogenase complex, SDH succinate 
dehydrogenase, SSADH succinic semialdehyde dehydrogenase, SUCL 
succinyl-CoA ligase
665Brain Structure and Function (2020) 225:639–667 
1 3
activity implies that these cells must obtain succinyl-CoA 
from some other metabolic pathway. Succinylations are 
widespread and may occur in an enzymatic (Gibson et al. 
2015; Wang et al. 2017; Kurmi et al. 2018) and non-enzy-
matic (Wagner and Payne 2013; Weinert et al. 2013) man-
ner. However, they all require succinyl-CoA. In mammals, 
this high-energy metabolite can be generated only through 
KGDHC, succinyl-CoA ligase, catabolism of valine, iso-
leucine, methionine, thymine, odd-number chain fatty 
acids (and perhaps propionate), and through the reaction 
catalyzed by OXCT1. Since glia may not exhibit KGDHC 
nor succinyl-CoA ligase components, provision of succinyl-
CoA is ensured only by the remaining pathways. Mindful 
of the remaining pathways generating succinyl-CoA inside 
the matrix, it is still a mystery how can there be extramito-
chondrial protein lysine succinylations. KGDHC compo-
nents have been observed in the nuclei of the human cell 
line U251 (Wang et al. 2017), in rat neonatal cardiac myo-
cytes, human-induced pluripotent stem cardiac myocytes, 
SW620 human colon cancer cells, and developing mouse 
embryonic heart (Choi et al. 2019); however, we did not 
observe KGDHC subunit immunoreactivity in the nuclei of 
our human fibroblasts, HeLa, and COS-7 cells, nor in the 
human cortical sections.
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